---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006996"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:10:17.587234+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools prelim Q4 revenue ~$56M, FY2025 ~$185M; SomaLogic sale on track

## Summary
- Q4 combined rev ~$56M (continuing ops ~$24M); FY2025 combined ~$185M (continuing ~$85M).
- Exceeded guidance and expectations for both combined and continuing operations.
- SomaLogic sale to Illumina on track to close H1 2026; expects ~$550M cash post-close.
- Base business on track to positive adjusted EBITDA; positioned for disciplined M&A.
- Streamlined operations and improved cost structure exiting year as leaner organization.

## SEC filing metadata
- accession: 0001193125-26-006996
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/0001193125-26-006996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/lab-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006996
- JSON: https://secwatch.observer/filing/0001193125-26-006996.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006996.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.